Common Prevention and Treatment Strategies for Gynecological Cancers

Authors

  • Xuanhongyi Zhang

DOI:

https://doi.org/10.61173/69w0gv61

Keywords:

Cancer, Prevention, Treatment

Abstract

Breast cancer, ovarian cancer and cervical cancer pose a serious threat to women’s health. Their initiation and progression are closely associated with multiple factors, including genetic susceptibility, abnormalities in DNA repair, viral infection and hormonal regulation. This review systematically summarizes the main preventive strategies and current treatment status of the three cancers. In terms of prevention, particular emphasis is placed on the roles of genetic screening, pharmacological interventions, HPV vaccination, and healthy lifestyle modifications in reducing cancer risk. Regarding treatment, the review outlines comprehensive therapeutic approaches based on surgery and radiotherapy/chemotherapy, combined with targeted therapy, immunotherapy, and maintenance therapy, and analyzes their advantages and limitations across different disease stages. Overall, precise screening and stageadapted treatment strategies can significantly improve patient prognosis; however, the appropriate populations and long-term efficacy of emerging therapeutic approaches require further investigation and validation. Future efforts should integrate molecular subtyping and biomarkers to optimize precision prevention and comprehensive treatment strategies for gynecological malignancies.

References

[1] Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell. 1999 Oct;4(4):511-8.

[2] Horner SM, DeFilippis RA, Manuelidis L, DiMaio D. Repression of the human papillomavirus E6 gene initiates p53- dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. J Virol. 2004 Apr;78(8):4063-73.

[3] Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011 Jun 23;364(25):2381-91.

[4] Nelson HD, Smith ME, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013 Apr 16;158(8):604-14.

[5] Harper DM, Navarro-Alonso JA, Bosch FX, Paavonen J, Stanley M, Sasieni P, Yébenes M, Martínez-Martínez N, Rodriguez Á, García A, Martín-Gomez L, Vallejo-Aparicio L, Carrión H, Ruiz García Y. Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: A systematic literature review. Hum Vaccin Immunother. 2025 Dec;21(1):2497608.

[6] Khodavandi A, Alizadeh F, Razis AFA. Association between dietary intake and risk of ovarian cancer: a systematic review and meta-analysis. Eur J Nutr. 2021 Jun;60(4):1707-1736.

[7] Arriagada R, Lê MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol. 1996 May;14(5):1558-64.

[8] Speers C, Pierce LJ. Postoperative Radiotherapy After Breast-Conserving Surgery for Early-Stage Breast Cancer: A Review. JAMA Oncol. 2016;2(8):1075–1082.

[9] Abrams, J.S. Adjuvant therapy for breast cancer — results from the USA consensus conference. Breast Cancer 8, 298–304 (2001).

[10] EBCTCG (Early Breast Cancer Trialists’ Collaborative Group); McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014 Jun 21;383(9935):2127-35.

[11] Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673- 84.

[12] Shimada M, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Minagawa Y, Ishihara K, Takeuchi Y, Okada M, Terakawa N. Outcome of patients with early ovarian cancer undergoing three courses of adjuvant chemotherapy following complete surgical staging. Int J Gynecol Cancer. 2005 Jul-Aug;15(4):601-5.

[13] Winter-Roach BA, Kitchener HC, Lawrie TA. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2012 Mar 14;3(3):CD004706. doi: 10.1002/14651858.CD004706. pub4. Update in: Cochrane Database Syst Rev. 2015 Dec 17;(12):CD004706.

[14] Polterauer S, Vergote I, Concin N, Braicu I, Chekerov R, Mahner S, Woelber L, Cadron I, Van Gorp T, Zeillinger R, Castillo-Tong DC, Sehouli J. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA- IV: analysis of the OVCAD data. Int J Gynecol Cancer. 2012 Mar;22(3):380-5.

[15] Franzese E, Diana A, Centonze S, Pignata S, De Vita F, Ciardiello F, Orditura M. PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts? Front Oncol. 2020 Jun 12;10:782.

Downloads

Published

2026-04-24

Issue

Vol. 4 No. 2 (2026): Volume 4, Issue 2

Section

Articles

License

Copyright (c) 2026 by the authors.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.